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RESUMO 
O cancro é uma das patologias mais agressivas e letais, permanecendo um desafio 
para investigadores e médicos, mesmo após décadas de investigação e investimento nesta 
área. A iniciação e progressão tumoral é processo complexo que depende de diversas 
interações entre o tumor e os tecidos circundantes. A capacidade dos tumores iludir a 
destruição pelo sistema imune, tornou-se um emergente Hallmark do cancro.  
O glioblastoma multiforme (astrocitoma grau IV) é o tipo mais comum e agressivo de 
tumor maligno cerebral. Pacientes com este tumor apresentam um prognóstico 
desfavorável e um tempo de sobrevida muito baixo. Deste modo, torna-se emergente a 
criação de novas terapias que superem as atuais limitações do tratamento.  
O objetivo principal deste estudo foi avaliar a capacidade imunomodeladora de 
produtos extracelulares de células de glioblastoma, in vitro. Para tal, foi avaliada a 
capacidade dos produtos extracelulares de culturas de células de glioblastoma recolhidos 
a diferentes tempos, quer em induzir a produção de IL-10 pelas células T quer em inibir a 
ativação de células T. Também foi avaliado o efeito dos produtos extracelulares na função 
e na diferenciação dos macrófagos.  
Os resultados mostraram que produtos extracelulares de células de glioblastoma têm 
uma capacidade imunomodeladora nas células imunitárias do hospedeiro. Mais 
especificamente, observou-se que estes produtos extracelulares foram capazes de inibir a 
ativação das células e induzir a produção de IL-10 em culturas de PBMC. 
Interessantemente, os produtos excretados pelas células de glioblastoma também induzem 
ativamente a polarização de monócitos em macrófagos M2, um fenótipo associado com 
uma resposta anti-inflamatória ou imunossupressora. É importante referir que estes efeitos 
podem ser observados mesmo se os produtos extracelulares forem obtidos a tempo muito 
precoces de culturas de células de glioblastoma.  
Em conclusão, estes resultados permitiram inferir um impacto dos produtos 
extracelulares de células de glioblastoma na supressão da resposta imune.  
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ABSTRACT 
Cancer is one of the most aggressive and lethal diseases, remaining a challenge for 
researchers and physicians despite decades of research and investment in this area. 
Tumour initiation and progression is a complex process that depends on several 
interactions between the tumour and surrounding tissues. The ability of tumours to evade 
its own destruction by the immune system has become an emerging hallmark of cancer. 
Glioblastoma multiforme (astrocytoma grade IV) is the most common and aggressive 
type of malignant brain tumour. Patients with this type of tumours have a poor prognosis 
and a low median overall survival. Thus, it becomes urgent to develop new therapies that 
overcome the current limitations of treatment.  
The aim of this study was to evaluate, in vitro, the immunomodulatory capacity of 
extracellular products of glioblastoma cells. To this end, it was evaluated the ability of 
extracellular products of glioblastoma cell cultures recovered at different time points, either 
to induce IL-10 production by T-cells or to inhibit T cell activation. It was also evaluated the 
effect of extracellular products in function and differentiation of macrophages. 
The results showed that extracellular products of glioblastoma cells have an 
immunomodulatory ability on host immune cells. More specifically, we observed that these 
extracellular products were able to inhibit T cell activation and to inducing IL-10 production 
by in PBMC cultures. Interestingly, the products excreted by glioblastoma cells also actively 
induce the polarization of monocytes into M2 macrophages, a phenotype associated with 
an anti-inflammatory or immune-suppressive response. Importantly, these effects could be 
observed even if the extracellular products were obtained at very early time points of 
glioblastoma cell cultures 
In conclusion, these results allow to infer an impact of extracellular products of 
glioblastoma cells in suppression of the immune response.
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I. INTRODUCTION 
Cancer is characterized by an abnormal mass of tissue, with survival and growth 
advantage, resulting in excessive proliferation. Malignant tumours have the capacity to 
invade and destroy adjacent structures, but can also spread to distant sites (metastasize) 
and lead to death (Kumar, V. et al. 2014). 
Carcinogenesis is the process that leads to the transformation of a normal cell into a 
neoplastic cell and is divided into three stages: initiation, promotion and progression. 
Tumour initiation involves exposure of normal cells to chemical, physical or biological 
carcinogens. These carcinogens cause genetic damage to deoxyribonucleic acid (DNA), 
providing proliferative advantage of initiated cells relative to surrounding normal cells. 
Tumour promotion is characterized by a proliferation of the initiated cells to a greater extent 
than normal cells, increasing the probability of additional genetic damage. Progression is 
the final stage of neoplastic transformation, where genetic and phenotypic changes and cell 
proliferation occur. This involves a fast increase in the tumor size, where the cells may 
undergo further mutations with invasive and metastatic potential  (Loeb, L.A. and Harris, 
C.C. 2008). 
Genetic and environmental factors contribute to the development of cancer, however 
environmental factors appear to be dominant for most cancer (Kumar, V. et al. 2014). 
Cancers caused by environmental agents frequently occur in tissues with the greatest 
surface exposure to the external environment such as lung cancer, gastrointestinal tract 
and skin (Loeb, L.A. and Harris, C.C. 2008). Age also has an important influence on the 
probability of developing a tumour. This effect can be explained by the fact that there is an 
accumulation of somatic mutations or a decline in immune competence, which accompanies 
aging (Kumar, V. et al. 2014). 
Cancer is the second most common cause of death following cardiovascular diseases, 
causing over 8 million deaths worldwide in 2013 (Fitzmaurice, C. et al. 2015). Lung, 
prostate, colorectal, stomach, and liver cancer are the most common types of cancer in 
men, while breast, colorectal, lung, cervix uterine, and stomach cancer are the most 
common among women (Ervik, M. et al. 2016). The treatment of patients with cancer has 
been based on a combination of treatment modalities: surgery, radiotherapy and 
chemotherapy (Balis, F.M. 1998). The main objective of this treatment is a cure and 
secondly prolong life and symptom relief (palliate) when the cure is not possible due to 
advanced disease (Khan, F.A. et al. 2005). 
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Tumour initiation and progression is a complex process that depends on several 
interactions between the tumour and surrounding tissues. Hanahan and Weinberg have 
identified a set of changes in cellular process that constituted essential properties or 
hallmarks of cancer. These hallmarks include sustained proliferative signalling, evasion of 
growth suppressors, resistance to cell death, replicative immortality, induction of 
angiogenesis, deregulation of cellular energetics, avoidance of immune destruction, 
tumour-promoting inflammation, genomic instability and mutation, and activation of invasion 
and metastasis. In 2011, Hanahan and Weinberg recognize that the immune system plays 
a critical role in the pathogenesis of cancer since tumours can avoid detection by the 
immune system and limit the extent of immune destruction by disrupting the processes of 
the cancer immunity cycle throughout the body (Hanahan, D. and Weinberg, R.A. 2011).  
 
1. Overview of the immune system 
The immune system has a complex architecture comprised of primary lymphoid organs 
(bone marrow and thymus) and secondary lymphoid organs (lymph nodes, spleen, Peyer’s 
patches, and mucosal tissues) and a variety of cells that interact and communicate via 
chemical conductors in order to orchestrate an immune response against foreign 
substances, as external aggressions of antigenic nature (macromolecules or 
microorganisms) and internal aggressions (transformed or tumour cells), keeping the 
homeostatic balance (Chaplin, D.D. 2006; Boehm, T. and Bleul, C.C. 2007; Arosa, F.A. et 
al. 2012; Elsabahy, M. and Wooley, K.L. 2013; Abbas, A.K. et al. 2014).  A fundamental 
property of the immune system is its ability to distinguish self from non-self, a condition 
which is referred to as the "process of immunological tolerance" or self-tolerance (Chaplin, 
D.D. 2010; Schwartz, R.H. 2012). 
Vertebrate immune system has two phases of response determined by the speed and 
specificity of the reaction: the innate and the adaptive immune response (Parkin, J. and 
Cohen, B. 2001). The innate and adaptive immune systems are often described as 
contrasting separate arms of the host response; however, they must act together and in a 
very coordinated fashion in order to ensure host protection from disease. This division helps 
us to understand the physiology of an immune response (Chaplin, D.D. 2010). 
Blood cells, which are categorized in either the myeloid or the lymphoid lineage, are 
generated from hematopoietic stem cells (Arosa, F.A. et al. 2012). Myeloid lineage cells 
include megakaryocytes and erythrocytes as well as monocytes (can be differentiated into 
macrophages) and granulocytes (neutrophils, basophils and eosinophils). Lymphoid 
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lineage cells include T, B and natural killer (NK) cells. Dendritic cells (DCs) are not clearly 
grouped either in lymphoid or myeloid lineage, because can arise from either common 
lymphoid progenitors or common myeloid progenitors (Kondo, M. 2010; Arosa, F.A. et al. 
2012; Elsabahy, M. and Wooley, K.L. 2013).  
 
1.1. Innate immunity  
Innate immunity (also called natural or native immunity) is the first line of defense 
against pathogens or other environmental threats, responding in a short period of time 
within minutes to hours, playing a crucial role in the early recognition and subsequent 
triggering of a protective inflammatory response to invading pathogens (Alberts, B. et al. 
2002; Mogensen, T.H. 2009). Moreover, innate immunity plays a central role in activating 
and modulating the subsequent adaptive immune response (Ezekowitz, R.A.B. and 
Hoffmann, J.A. 2002; Turvey, S.E. and Broide, D.H. 2010). 
The primary function of innate immunity is the recruitment of immune cells to sites of 
infection and inflammation through the production of cytokines (small proteins involved in 
cell-cell communication) (Warrington, R. et al. 2011).  
The main components of innate immunity (figure 1) include (1) physical and chemical 
barriers, such as epithelia and antimicrobial chemicals produced at epithelial surfaces; (2) 
effector cells such phagocytic cells (neutrophils and macrophages), DCs, NK cells and other 
innate lymphoid cells; (3) mechanisms of pattern recognition (Toll-like receptors); and (4) 
humoral mechanisms, such as members of the complement system and other mediators of 
inflammation (cytokines that regulate the function of other cells, chemokines that attract 
inflammatory leukocytes, lipid mediators of inflammation, and bioactive amines and 
enzymes) (Chaplin, D.D. 2006; Abbas, A.K. et al. 2014; Raval, R.R. et al. 2014). 
Tissue-resident innate immune cells, such as DCs, macrophages, mast cells or even 
epithelial cells have surface and intracellular receptors that recognize evolutionarily 
conserved structures on pathogens, known as pathogen-associated molecular patterns 
(PAMPs) (Arosa, F.A. et al. 2012; Madureira, P. et al. 2015). This recognition is done 
through a limited number of germ line-encoded pattern recognition receptors (PRRs). PRRs 
are found on practically all cells of the body and can be expressed as surface, intracellular 
or secreted (decoy) receptors. There are several classes of PRRs, including Toll-like 
Receptors (TLRs), C-type Lectin Receptors (CLRs), Retinoic acid-inducible gene I-Like 
Receptors (RLRs), Nucleotide oligomerization domain-Like Receptors (NLRs) and cytosolic 
DNA sensors (Thompson, M.R. et al. 2011). Ligand-binding to PRRs results in production 
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of a variety of pro-inflammatory and antiviral cytokines and chemokines, subsequently 
inducing adaptive immune responses (Mogensen, T.H. 2009; Murphy, K.M. 2011; Cui, J. et 
al. 2014). The same PRR that engage pathogen-associated molecules are also able to 
recognize stress-related self-molecules, so-called danger-associated molecular patterns 
(DAMPs). DAMPs include altered proteins such as β-amyloid fibres, heat-shock proteins, 
cholesterol and uric acid deposits. Both, PAMPs and DAMPs are recognized by our immune 
system and induce strong inflammatory responses - danger signals (Madureira, P. et al. 
2015). 
The important ability of the innate immune system to recognize and limit microbes early 
during infection is based primarily on employment of complement activation, phagocytosis, 
autophagy, and immune activation by different families of PRRs (Mogensen, T.H. 2009).  
 
Figure 1 - The innate and adaptive immune systems and the overlap between them. Innate immunity is 
the first line of defence and involve nonspecific responses to foreign infectious agents. These include cellular 
functions such as phagocytosis and endocytosis by macrophages and neutrophils. Innate immunity plays a 
central role in activating and modulating the subsequent adaptive immune response through the recognition of 
pathogen-associated molecular patterns (PAMPs) by pattern-recognition receptors (PRRs), such as Toll-like 
receptors (TLRs) and NOD-like receptors (NLRs). Adaptive immune mechanisms involve the engagement of 
receptors that are selected for reactivity with specific antigens (T-cell receptors (TCRs) and immunoglobulin 
receptors on B cells). The full development of these responses requires the expansion and differentiation of the 
specific responder cells, which establishes a memory for the specific antigen response. (Adapted from: 
Gregersen, P.K. and Behrens, T.W. 2006). APC, antigen-presenting cell;  BCR, B-cell receptor; CLR, C-type 
Lectin Receptors; CRP, C-reactive protein; IL, interleukin; MBP, mannan-binding protein; NLR, NOD-like 
receptors; PPR, pattern recognition receptor; RLR, RIG-I-like receptor; TLR, toll-like receptor; TNF, tumour 
necrosis factor. 
 
Neutrophils, monocytes, DCs and macrophages are commonly designated as 
“professional” phagocytic cells and play a crucial role in host defense due to their ability to 
recognize and eliminate invading pathogens (Steevels, T.A. and Meyaard, L. 2011). 
PRRs 
(e.g. TLRs, NLRs, 
RLRs, CLRs) 
Foreign substances  
(e.g. bacteria, 
tumour cells) 
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Phagocytic cells produce reactive oxygen species (ROS), inflammatory cytokines, and 
chemokines, leading to bacterial killing and to recruitment and activation of additional 
immune cells (Steevels, T.A. and Meyaard, L. 2011). 
 
1.1.1. Macrophages 
Macrophages are antigen-presenting cells (APC) that play a central role in the clearance 
of invading pathogens by phagocytosis, production of ROS and nitrogen species and 
instruction of the other immune cells (Linehan, E. 2015). They are derived from monocytes 
that differentiate from monoblasts in the bone marrow. Upon tissue damage or infection, 
monocytes are rapidly recruited to the tissue, where differentiate into mature macrophages 
(Murray, P.J. and Wynn, T.A. 2011; Yang, J. et al. 2014).  
Macrophages are highly plastic cells, which allows them to polarize in different 
phenotypes (figure 2) according to signals produced in the local microenvironment: 
classically activated macrophages (M1 macrophages) and alternatively activated 
macrophages (M2 macrophages) (Genin, M. et al. 2015; Linehan, E. 2015). 
Bacterial cell wall components such as lipopolysaccharides (LPS), interferon (IFN)-γ 
produced by NK, T helper 1 (Th1) cells, granulocyte macrophage colony-stimulating factor 
(GM-CSF) and TLR agonists polarize macrophages towards the M1 phenotype (Chanmee, 
T. et al. 2014; Martinez, F.O. and Gordon, S. 2014; Genin, M. et al. 2015). Upon activation, 
M1 macrophages produce proinflammatory cytokines like tumour necrosis factor (TNF)-α, 
interleukin (IL)-1β, IL-6 and IL-12, nitric oxide (NO) and reactive oxygen intermediates, pro-
inflammatory chemokines and express high levels of the major histocompatibility complex 
(MHC) class I and class II molecules. M1 phenotype drives pro-inflammatory, cytotoxic and 
anti-tumour responses (Chanmee, T. et al. 2014; Wang, N. et al. 2014).  
In contrast, M2 macrophage polarization can be induced by IL-4 and IL-13, TLRs and 
immune complexes, IL-1 receptor ligands, IL-10, macrophage colony-stimulating factor (M-
CSF), transforming growth factor (TGF)-β, and glucocorticoids (Hao, N.B. et al. 2012; 
Martinez, F.O. and Gordon, S. 2014; Genin, M. et al. 2015). M2 macrophages express high 
levels of scavenger receptor, mannose receptor, IL-1 receptor antagonist, and IL-1 decoy 
receptor and produce a high level of IL-10, which lead M2 macrophages to mainly promote 
angiogenesis, immunosuppression, and tumour progression (Hao, N.B. et al. 2012). 
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Figure 2 - Macrophage polarization and its function. Macrophages can polarize into M1 (also known as 
classically activated) and M2 (also known as alternatively activated) macrophages that have distinct functional 
phenotypes. M2 macrophages do not constitute a uniform population and often are further subdivided into M2a, 
M2b, M2c and M2d categories. The common denominator of all four subpopulations is high IL-10 production 
characteristic of its immunosuppressive function.  (Adapted from: Chanmee, T. et al. 2014). GC, glucocorticoid; 
IC, immune complex; IFN, interferon; IL, interleukin; IL-1ra, IL-1 receptor antagonist; LPS, lipopolysaccharides; 
MHC, major histocompatibility complex; MR, mannose receptor; SR, scavenger receptor; TGF, transforming 
growth factor; TLR, toll-like Receptor; TNF, tumour necrosis factor. 
 
1.1.2. Dendritic cells 
Dendritic cells (DCs), a class of bone-marrow-derived cells, are known as APCs 
"professional" and have the ability of linking the innate and adaptive immune systems. This 
cells play a key role in inducing and maintaining the anti-tumour immunity, however in the 
tumour environment their antigen presenting function may be impaired (Ma, Y. et al. 2013). 
Immature DCs are highly reactive to molecules released by damaged tissues (uric acid), 
products derived from pathogens (LPS, bacterial DNA and viral RNA) and inflammatory 
cytokines (TNF-α, IL-1 and IL-2). In the presence of these stimuli, DCs undergo a 
phenotypic and functional maturation process (Arosa, F.A. et al. 2012; Abbas, A.K. et al. 
2014). Upon phagocytosis and peptide processing, mature DCs display different types of 
antigens, including tumour antigens, via MHC class I or class II molecules to naïve T cell, 
for generate robust antigen-specific T cell immune responses. There are two major subsets 
of DCs: myeloid DCs (mDCs; also known as conventional DCs and classical DCs) and 
plasmacytoid DCs (pDCs). Tumour-associated DCs (TA-DCs) is another subtype of DCs 
identified in the tumour microenvironment (TME) with associated immunosuppressive 
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responses (Palucka, K. and Banchereau, J. 2012; Ma, Y. et al. 2013; Mantia-Smaldone, 
G.M. and Chu, C.S. 2013; Abbas, A.K. et al. 2014). 
DCs can be utilized as therapeutic cancer vaccines in order to induce tumour-specific 
effector T cells that can induce tumour regression and/or eradication and can induce 
immunological memory to control tumour relapse. Typically, DCs are isolated from the 
patient’s blood, and then are stimulated in the lab with cancer antigens and cytokines. After 
this the cells are injecting back into the patient in order to stimulate the immune response 
(Palucka, K. and Banchereau, J. 2012; Mantia-Smaldone, G.M. and Chu, C.S. 2013). The 
potential role of DCs in cancer immunotherapy have expanded remarkably, and there is a 
new array of therapeutic options (figure 3). 
 
Figure 3 - Therapeutic options with DCs. A| The endogenous vaccination with dendritic cells results from in 
vivo antigen release owing to immunogenic cell death in response to chemotherapy, radiotherapy and 
immunomodulation approaches that are targeted at T cells. B| Antigens can be directly delivered to DCs in vivo 
using chimeric proteins that are comprised of an antibody that is specific for a DC receptor fused to a selected 
antigen. C| Targeting DCs in the tumour microenvironment to reprogramme pro-tumour inflammation leading to 
tumor rejection D | Vaccines can be based on ex vivo-generated tumor antigen-loaded DCs that are injected 
back into patients. (Adapted from: Palucka, K. and Banchereau, J. 2012) DC, dendritic cells; MHC, major 
histocompatibility complex; TLR, toll-like receptor. 
 
1.1.3. Natural killer cells  
NK cells were first identified in 1975 as large granular lymphocytes with the ability to 
eliminate certain types of tumour cells without prior activation (Arosa, F.A. et al. 2012; 
Cheng, M. et al. 2013). Nowadays, there is a better understanding of the biology and 
function of NK cells.  These cells develop in bone marrow from common lymphoid 
 INTRODUCTION 
 
8 
 
progenitor cells, and are defined as CD3−CD56+ lymphocytes, which are distinguished as 
CD56bright and CD56dim subsets (Caligiuri, M.A. 2008; Cheng, M. et al. 2013).  
NK cells are characterized by the absence of a TCR and its activation dependent on the 
balance between inhibitory and activating signals from invariant receptors. Activation of NK 
cells results in the secretion of cytokines that regulate the innate (phagocytosis, antigen 
presentation) and adaptive (differentiation of T and B cells) immune response, and the 
elimination of target cells by cytotoxic process, which can involve the production of granules 
cytotoxic, as well as the aggregation of receptors that induce cell death (Arosa, F.A. et al. 
2012; Eguizabal, C. et al. 2014).  
NK cells play critical roles in the early control of viral infection, in hematopoietic stem 
cell transplantation, in reproduction and in tumour immunosurveillance (Cheng, M. et al. 
2013).  
During tumour progression, tumour cells develop several mechanisms to escape control 
from NK cells, such as the loss of expression of adhesion molecules, costimulatory ligands 
or ligands for activating receptors, the upregulation of MHC class I, soluble MIC, FAS ligand 
(FASL) or NO expression, the secretion of immunoregulatory molecules or 
immunosuppressive modulators such as indoleamine 2,3-dioxygenase (IDO), prostaglandin 
E (PGE) 2, and TGF-β . Several abnormalities of NK cells have been observed in cancer 
patients, including overexpression of inhibitory receptors, decreased cytotoxicity, defective 
expression of activating receptors or intracellular signalling molecules, defective 
proliferation, decreased numbers in peripheral blood and in tumour infiltrate, and defective 
cytokine production, opening new avenues for NK-based immunotherapeutic approaches 
(Waldhauer, I. and Steinle, A. 2008; Cheng, M. et al. 2013; Chretien, A.S. et al. 2014; 
Eguizabal, C. et al. 2014). 
 
1.1.4. Gamma delta (γδ) Τ cells 
γδ Τ cells represent a small subset of T cells that express a distinct TCR composed of 
γδ chains, not requiring the help of conventional MHC class I and class II molecules for 
recognizing the antigens (Bonilla, F.A. and Oettgen, H.C. 2010). γδ T cells bridge innate 
and adaptive immunity, through a wide range of defense mechanisms against 
microorganisms and diseases like cancer (Bonilla, F.A. and Oettgen, H.C. 2010; Gogoi, D. 
and Chiplunkar, S.V. 2013). 
In the tumour environment, there is an accumulation of metabolites of the mevalonate 
pathway – phosphoantigens - which are a powerful danger signal for the immune system, 
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leading to γδ T cells activation in a TCR dependent manner (Gogoi, D. and Chiplunkar, S.V. 
2013). Human γδ T cells can act as professional APC because they can process and display 
antigens and can also provide co-stimulatory signals necessary for the induction of 
proliferation, differentiation and target cell killing. The activation of effector γδ T cells leads 
to production of the anti-tumour cytokines, such as IFN-γ and TNF-α; induction of apoptosis 
of transformed cells through engagement of death-inducing receptors as FAS, TNF-related 
apoptosis-inducing ligand receptors (TRAILR); and release of perforins and granzymes that 
directly kill tumour cells. In the presence of anti-tumour cell monoclonal antibodies, γδ T 
cells express CD16 promoting antibody-dependent cellular cytotoxicity (ADCC). γδ T cells 
can induce a robust NK cell-mediated anti-tumour cytotoxicity through engagement of the 
CD137 pathway (Bonneville, M. et al. 2010; Braza, M.S. and Klein, B. 2013). 
Intratumoral γδ T cell infiltration has a variable prognostic value: from positive 
(melanoma) to neutral (renal cancer) to negative (breast cancer and colorectal cancer) 
correlations with patient outcomes (Silva-Santos, B. et al. 2015). 
 
1.2. Adaptive immunity  
In contrast to innate immunity, adaptive immunity is a late immune response, but 
manifests exquisite specificity for its target antigens by virtue of the antigen-specific 
receptors expressed on the surfaces of T and B lymphocytes (figure 1). Another 
characteristic of adaptive immunity is the ability to manifest immune memory, ensuring a 
more vigorous response against specific pathogens or toxins when they are encountered a 
second time. Immunological memory can persist even decades after the initial sensitizing 
encounter. The principal cells of the adaptive immune system are lymphocytes and their 
secreted products (such as antibodies) (Chaplin, D.D. 2006; Chaplin, D.D. 2010;Abbas, 
A.K. et al. 2014). 
Adaptive immunity is divided into two types of immune responses: humoral immunity 
and cellular immunity. Humoral immunity is involved in the eradication of microbes present 
in the blood or fluid by generating antibodies, which are produced by B cells. On the other 
hand, cellular immunity is mediated by T cells, and is responsible for the eradication of 
cancer cells and microbes hidden inside cells (Akira, S. 2011; Abbas, A.K. et al. 2014).  
1.2.1. T cells and cellular immunity 
T cells derive from hematopoietic stem cells in bone marrow and, following migration, 
mature in the thymus. These cells express a unique antigen-binding receptor on their 
membrane, known as the T-cell receptor (TCR), which requires the action of APCs (usually 
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dendritic cells, but also macrophages, B cells, fibroblasts and epithelial cells) to recognize 
a specific antigen (Warrington, R. et al. 2011). 
T cells recognize peptide fragments of antigens that have been taken up by APCs 
through the process of phagocytosis or pinocytosis (Chaplin, D.D. 2010). APCs engulf and 
digest foreign antigens and present fragments of the antigens associated with surface-
exposed MHC molecules (also designated human leukocyte antigen or HLA) to T cells. 
There are two classes of MHC molecules that present fragments of proteins that either have 
been synthesized within the cell (class I MHC molecules) or that have been ingested by the 
cell and proteolytically processed (class II MHC molecules). Unlike MHC class I expression, 
which is constitutive in all nucleated cells, MHC class II molecules are present on APCs 
where its expression is up-regulated by innate immune stimuli, including ligands for TLRs 
(Chaplin, D.D. 2006).  
Interaction between the TCR and peptide-MHC provides only a partial signal for cell 
activation. Full activation requires the additional interaction between the costimulatory 
molecule CD28 on the T cell and CD80 or CD86 (also designated B7.1 and B7.2, 
respectively) on the APC (Chaplin, D.D. 2006). The MHC-antigen complex activates the 
TCR and the T cell secretes cytokines which further control the immune response. This 
antigen presentation process stimulates naïve CD4+ or CD8+ T cells to differentiate into 
either T helper (Th) cells (CD4+ cells) or cytotoxic T (Tc) cells (CD8+ cells), depending on 
the cytokines and costimulatory signals they receive during the activation process (Chaplin, 
D.D. 2006; Warrington, R. et al. 2011). 
T-cell effector subsets 
CD8+ T cells represent a major fraction of circulating T cells and are important in the 
defence against intracellular pathogens and transformed cells. Once activated, naïve CD8+ 
T proliferate and can differentiate into effectors (cytotoxic T lymphocytes or CTLs) and 
memory CD8+ T cells. The different subsets of CD8+ T cells are shown in figure 4 (Bonilla, 
F.A. and Oettgen, H.C. 2010; Murphy, K.M. 2011). These cells can be identified by 
differential expression of cell surface markers including CD3 and CD8 and IFN- production. 
CTLs are responsible for the direct killing of infected, damaged, and dysfunctional cells, 
including tumour cells, by secretion of perforin and granzymes, which cause apoptosis of 
target cells (Dong, C. and Martinez, G.J. 2010).  
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Figure 4 - The differentiation of CD8+ T cells and different CD8+ subsets. Naïve T cells differentiate into 
stem cell memory cells (TSCM), T Central Memory cells, (TCM), T effector memory cells (TEM), and T effector cells 
(TEFF). L-Selectin, CD45RO, CD45RA and CCR-7 are the different CD8+ markers upon cell differentiation. The 
memory function and proliferation are decreased, while the effector function is increased upon CD8+ T cell 
differentiation (Adapted from: Golubovskaya, V. and Wu, L. 2016). 
 
CD4+ T cells or T helper (Th) cells differentiate into several subsets of effector T cells 
with a variety of different functions. The main functional classes are Th1, Th2, Th17, T 
follicular helper (Tfh) and regulatory T (Treg) cells, which are characterized by different 
cytokine profiles and have different functions (figure 5) (Murphy, K.M. 2011). CD4+ αβ TCR 
population have little cytotoxic activity and secrete cytokines that act on other leucocytes 
such as B cells, macrophages, eosinophils, or neutrophils to clear pathogens (Bonilla, F.A. 
and Oettgen, H.C. 2010). Th can be identified by differential expression of cell surface 
markers including CD3 and CD4 (Elsabahy, M. and Wooley, K.L. 2013).  
 
Figure 5 - Different subsets of CD4+ T cells. Naïve CD4+ T cells can differentiate into distinct effector T-helper 
and regulatory T-cell subsets, depending on the nature of antigen stimulation signal received from APCs. The 
different CD4+ subsets are characterized by expression of lineage-specific transcriptional regulators, cell surface 
 INTRODUCTION 
 
12 
 
markers, and secretion of key cytokines. (Reprinted from: Bonilla, F.A. and Oettgen, H.C. 2010; Dong, C. and 
Martinez, G.J. 2010; Murray, P.J. and Wynn, T.A. 2011; Elsabahy, M. and Wooley, K.L. 2013; Ma, C.S. and 
Deenick, E.K. 2014; Tripathi, S.K. and Lahesmaa, R. 2014). BCL-6, B cell lymphoma 6;CCL, CC-chemokine 
ligand; FOX, forkhead box; GATA3, GATA-binding protein 3; IFN, interferon; IL, interleukin; ROR, retinoic acid 
receptor-related orphan receptor; T-bet, T-box expressed in T cells; Tfh, T follicular helper; TGF, transforming 
growth factor; Th, T helper; TNF, Tumour necrosis factor.  
 
Regulatory T (Treg) cells, a small subpopulation of CD4+ T cells, play a crucial role in 
the maintenance of peripheral immunological tolerance and control of immune responses 
toward pathogens and tumours. These cells are a heterogeneous population with respect 
to their origin of development, functional activity and activation status. They use diverse 
suppressive mechanisms depending on microenvironments and target cells, including 
inhibitory cytokines (e.g., IL-10, IL-35 and TGF-β), cytolysis, metabolic disruption or the 
modulation of dendritic cell function (Guo, J. and Zhou, X. 2015). Treg cells are generally 
categorized into two groups: thymus-derived Treg (tTreg) cells and peripherally-derived 
Treg (pTreg) cells, also known as natural Treg (nTreg) and induced Treg (iTreg), 
respectively (figure 6) (Ohkura, N. et al. 2013; Li, Z. et al. 2015). 
 
Figure 6 - Natural and induced regulatory T cells. Regulatory T cells are broadly classified into natural or 
induced. Natural Tregs are CD4+CD25+ T-cells which develop, and emigrate from the thymus to perform their 
key role in immune homeostasis. Induced Tregs are non-regulatory CD4+ or CD8+ T-cells which acquire CD25 
(IL-2R alpha) expression outside of the thymus, and are typically induced by inflammation and disease 
processes, such as autoimmunity and cancer. (Adapted from: Mills, K.H.G. 2004). CD, cluster differentiation; 
FOXP3, forkhead box protein 3; TH3, TGF-β producing T helper 3; TR1, IL-10–producing type 1 regulatory cells. 
 
The natural self-antigen-reactive CD4+CD25+ Treg are generated in the thymus and 
then enter peripheral tissues, where they suppress the activation of other self-reactive T 
cells. These cells express the transcription factor forkhead box protein 3 (FOXP3) and 
highly express surface and intracellular markers, including CD25, glucocorticoid-induced 
tumour necrosis factor receptor family related gene (GITR) and cytotoxic T lymphocyte-
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associated protein 4 (CTLA-4) and mediate immune suppression through a cell–cell contact 
mechanism (Dasgupta, A. and Saxena, R. 2012; Li, B. and Wang, R.-F. 2012; Okada, M. 
et al. 2014; Guo, J. and Zhou, X. 2015).   
Other populations of antigen-specific regulatory T cells can be induced from naïve 
CD4+CD25- or CD8+CD25- T cells in the periphery under the influence of semi-mature 
dendritic cells, IL-10, TGF-β and possibly IFN-α (figure 7). The inducible populations of 
regulatory T cells include IL-10–producing type 1 regulatory (TR1) cells and TGF-β 
producing T helper 3 (TH3) cells (Wan, Y.Y. and Flavell, R.A. 2007; Murphy, K.M. 2011; Li, 
B. and Wang, R.-F. 2012; Yao, Y. et al. 2015). CD8+ regulatory T cells are a subtype CD8+ 
T cells that secrete either IL-10 or TGF-β, leading to the suppression of the anti-tumour 
activity of CTLs and NK cells (Mills, K.H.G. 2004). 
 
Figure 7 - Targets of regulatory T cells and mechanisms of suppression. CD4+CD25+ Treg cells express: 
CD25, which required for Treg cell survival (and presumably for IL-2 absorption as part of Treg cell-mediated 
suppression); CTLA-4, which is involved in the suppressive function of Treg cells by downregulating CD80 and 
CD86 expression on antigen-presenting cells; and FOXP3, which is essential for Treg cell development and 
suppressive activity, partly through the maintenance of high levels of CD25 and CTLA-4 expression. These cells 
also secrete TGF-β or IL-10, which have a role in suppression. TR1 cells, TH3 cells and CD8+ regulatory T cells, 
secrete IL-10 and/or TGF-β. These immunosuppressive cytokines inhibits antigen-presenting cells by reducing 
the expression of MHC molecules and costimulatory molecules, and blocks T -cell cytokine production. (Adapted 
from: Mills, K.H.G. 2004). APC, antigen-presenting cell; CD, cluster differentiation; CTL, cytotoxic T lymphocyte; 
CTLA-4, cytotoxic T lymphocyte-associated protein 4; FOXP3, forkhead box protein 3; IFN, interferon; IL, 
interleukin; MHC, major histocompatibility complex; TCR,T cell receptor; TGF, transforming growth factor; Th, 
T helper cell; TH3, TGF-β producing T helper 3; TR1, IL-10–producing type 1 regulatory cells; Treg, regulatory T 
cell. 
 
Natural regulatory T cell Induced regulatory T cell 
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Treg cells are found at high frequencies in tumour tissues of various types of cancers. 
In TME, Treg cells play a significant role in the suppression of anti-tumour immune 
responses against cancer cells. There is a heterogeneity in tumour-associated Treg cells, 
suggesting that they are accumulated by different mechanisms such as peripheral 
recruitment, proliferation of cells in the TME, or differentiation of progenitors in response to 
tumour-secreted factors (Quail, D. and Joyce, J. 2013). High FOXP3+ Tregs infiltration was 
significantly correlate with reduced overall survival in some tumour types, including breast 
cancer, melanoma and hepatocellular carcinoma; whereas, FOXP3+ Tregs were associated 
with improved survival in colorectal, head and neck, and oesophageal cancers (Quail, D. 
and Joyce, J. 2013; Shang, B. et al. 2015) . 
Th17 cells are generated in the presence of IL-6 and TGF-β, under the control of the 
transcription factor retinoic acid receptor related orphan receptor (ROR)t and signal 
transducer and activator of transcription 3 (STAT3). These cells secrete IL-17A, IL-17F, IL-
21, IL-22 and CC-chemokine ligand (CCL)-20 (Gnerlich, J.L. et al. 2010; Ye, J. et al. 2013).  
Th17 cells are often associated with tumours. Increased levels of tumour infiltrating 
Th17 cells have been detected in many human cancers, including ovarian, melanoma, 
breast, pancreatic, renal cell, and gastric cancer. Intratumoral Th17 cell infiltration has a 
variable prognostic value. In ovarian cancer, prostate cancer, lung carcinoma, and 
squamous cell carcinoma, Th17 cell infiltration was correlated with better survival, while in 
hepatocellular, colorectal, pancreatic, and hormone resistant prostate carcinoma patients 
was correlated with bad prognosis (Gnerlich, J.L. et al. 2010; Guery, L. and Hugues, S. 
2015).  
 
1.2.2. B cells and humoral immunity 
The humoral immune response is mediated by antibodies that are secreted by plasma 
cells that develop from B cells (Bonilla, F.A. and Oettgen, H.C. 2010). B cell development 
occurs in the bone marrow with gene recombination in the immunoglobulin locus, which 
results in the surface expression of a unique B cell receptor (BCR) (Batista, F.D. and 
Harwood, N.E. 2009). 
After the recognition of antigens in association with MHC class II molecules by BCR and 
PRR ligands, CD4+ T-cell help are recruited and naïve mature B cells proliferate and 
differentiate into effector B cells (plasma cells) or memory B cells (figure 8) (Nothelfer, K. et 
al. 2015). Plasma cells are generated during the primary response and are characterized 
by the production of antigen-specific immunoglobulins (antibodies), mostly immunoglobulin 
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M (IgM) (but some IgG) (Gray, D. 2002; Nothelfer, K. et al. 2015). Memory B cells are long 
lived and can quickly be reactivated to differentiate into plasma cells following secondary 
infection. Together, memory B cells and long-lived plasma cells form the basis for lifelong 
B cell-mediated protection against infections (Nothelfer, K. et al. 2015).  
 
Figure 8 - B cell responses to infection. In response to activation signals, naive mature B cells proliferate and 
differentiate into effector cells. The integration of several infection-related signals, including binding of specific 
antigens to the B cell receptor (BCR) and pattern recognition receptor (PRR) ligands results on B cell activation. 
At an early stage, short-lived plasma cells that secrete polyreactive antibodies can be induced. Regulatory B 
cells can also be generated leading to the production of immunosuppressive cytokines such as IL-10, IL-17, IL-
35 and TGF-β, which modulate T cell responses. Sustained B cell activation leads to further differentiation and 
selection in organized lymphoid structures, called germinal centres. The activation of nuclear factor-κB (NF-κB) 
and upregulation of activation-induced cytidine deaminase (AID) induce affinity maturation of antibodies through 
somatic hypermutation and class-switch recombination of the antibody heavy chain. This ultimately results in 
the differentiation of specific, long-lived plasma cells and memory B cells, which confer protective immunity. 
(Adapted from: Nothelfer, K. et al. 2015). Ig, immunoglobulin; IL, interleukin; TGF, transforming growth factor. 
 
2. Cancer and the immune system   
After years of controversy, it is now accepted the hypothesis that the immune system 
influence the development and biology of cancer. Nowadays, there is a clearer 
understanding of the ways by which tumour cells escape the host response, leading 
Hanahan and Weinberg (2011) to recognize that the ability to evade immune destruction is 
an emerging hallmark of cancer. With this, there is the emergence of new therapies that 
enable the host immune system to recognize and eliminate cancer cells (Kumar, V. et al. 
2014; Lam, S.S. et al. 2015). 
 
2.1. Immunosuppressive microenvironment of the tumour  
In the 1860s, Rudolf Virchow observed a tumour-promoting function for leukocytes 
leading him to create the hypothesis that cancer arises from inflammatory sites. The notion 
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that the immune system could repress tumour development was initially proposed in 1909 
by Paul Ehrlich, and almost 50 years later Lewis Thomas and Macfarlane Burnet proposed 
the so-called immunosurveillance hypothesis for cancer that ascribes to the immune system 
the ability to recognize and eliminate newly emerging cancer cells (Dunn, G.P. et al. 2002; 
Dunn, G.P. et al. 2004; Dadi, S. et al. 2016).  The action of NK cells and CD8+ T cells is 
chief in this immunosurveillance theory, because they are able to recognize and rapidly kill 
recently formed cancer cells (Madureira, P. et al. 2015).  
More recently, the term cancer immunosurveillance was refined and extended giving 
rise to the immunoediting hypothesis, which comprises three sequential phases that are 
termed the “three Es of cancer immunoediting:” elimination, equilibrium, and escape (figure 
9) (Dunn, G.P. et al. 2004). In the elimination phase, nascent transformed cells can be 
detected and eliminated by innate and adaptive immune system, through activation of 
immune effector cells, such as NK and T cells and by the release of effector molecules, 
such as IFN-γ, perforin, FAS/FASL, and TNF-related apoptosis-inducing ligand (TRAIL) 
(Kim, R. et al. 2007; Mittal, D. et al. 2014). The equilibrium phase is the next step in cancer 
immunoediting in which a continuous sculpting of tumour cells produces cells resistant to 
immune effector cells, leading to the immune selection of tumour cells with reduced 
immunogenicity (Kim, R. et al. 2007). If tumours circumvent immune recognition and/or 
destruction, they progress from the equilibrium to the escape phase, becoming clinically 
apparent (Teng, M.W. et al. 2015). The escape phase is characterized by the inability of the 
immune system in eliminating and controlling the proliferation of tumour cells. The cancer 
may occur as a result of exhaustion of the immune system or when cancer cells acquire 
phenotypic changes, allowing them to evade or avoid the immune system (Dunn, G.P. et 
al. 2006).  
Tumours can evade the immune system by mechanisms of immune tolerance, resulting 
in inactivation or tolerization of anti-tumour T cells through several mechanisms induced by 
tumour or accessory cells. Tumour escape of adaptive immunity may result specifically by 
elimination of T lymphocytes, the functional inactivation by tolerization/anergy mechanisms 
or by immunosuppressive cytokines or cells, or it may result from the fact that the 
lymphocytes are not exposed to tumour antigens - "immunological ignorance" (Abbas, A.K. 
et al. 2014). 
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Figure 9 - The three phases (3 Es) of cancer immunoediting: Elimination, Equilibrium, and Escape. 
Tumours may be eliminated in either the elimination or equilibrium phase, leading to protection from tumour 
growth. However, tumours may ultimately escape immune protection and become clinically manifest in the 
escape phase. (Adapted from: Swann, J.B. and Smyth, M.J. 2007). ARG, arginine; DR5, death receptor 5; IDO, 
indoleamine 2,3-dioxygenase; IFN, interferon; IL, interleukin; MICA/B, MHC class I chain–related antigens A 
and B; NKG2D, natural Killer group 2D; RAE1, retinoic acid early transcript 1; sMICA/B, soluble MICA/B; ULBP, 
UL16-binding protein.  
 
However, none of these hypotheses explains why our immune system is not able to 
recognize and eliminate tumours.  The most probable explanation is lacking danger signal.  
These danger signals are delivered by PAMPs or DAMPs that are recognized by specific 
receptors at the surface of innate immune cells, triggering an inflammatory response. The 
tumour rejection occurs when a tumour-associated antigen (TAA) is presented under a 
danger environment. When a TAA is presented in a context of non-danger, occurs tolerance 
induction and tumour development (Madureira, P. et al. 2015).  
There are a large number of mechanisms, which contribute for the high tolerogenic and 
immunosuppressive microenvironment found in tumours, including: development of an 
immunosuppressive tumour environment due to the release of cytokines (VEGF, IL-6, IL-
10, M-CSF and TGF-β) and immunoregulatory molecules (IDO, CTLA-4, PD-1/PD-L1, Tim-
3/ galectin-9, CD39, CD73, LAG-3, arginase, adenosine receptors);  loss of tumour 
antigens, MHC class I or co-stimulatory molecules, which leads to reduced immune 
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recognition; and increased resistance or survival by increased expression of STAT3 and 
anti-apoptotic molecule Bcl2 (Mittal, D. et al. 2014). 
 
2.2. Alpha-Fetoprotein: an example of immunomodulation in cancer  
Alpha-fetoprotein (AFP) is an oncofetal protein synthesized in the yolk sac and fetal 
liver, which is transcriptionally repressed shortly after birth. High levels of AFP are 
expressed in abnormalities of prenatal development and several epithelial cancers, 
including hepatocellular carcinoma (HCC). AFP is a TAA which is expressed in about 60% 
of HCC. It plays a role in the transport of serum components, interfere with intracellular 
signalling and has an immunoregulatory role (Gonzalez-Carmona, M.A. et al. 2006; Pardee, 
A.D. et al. 2014). 
Pardee et al. reported that AFP exerts immunosuppressive activity inducing dysfunction 
of DCs. They examined the effects of cord blood–derived normal AFP (nAFP) or HCC 
tumour-derived AFP (tAFP) on DC differentiation and function. In this study, they showed 
that tAFP-conditioned DCs expressing reduced levels of DC maturation markers, maintain 
a monocyte-like morphology and exhibit limited production of inflammatory mediators, 
limiting the induction of robust T cell proliferative responses. They also observed that full-
length AFP protein, along with the presence of low molecular mass copurifying species, is 
absolutely essential for tAFP to exert its immunosuppressive activity (Pardee, A.D. et al. 
2014).  
Thus, the tAFP can be used as a therapeutic target, through approaches that antagonize 
its regulatory properties in order to enhance immunity and improve the clinical outcomes 
(Pardee, A.D. et al. 2014). 
 
3. Glioblastoma 
Gliomas are a common type of primary brain tumour and include astrocytomas, 
oligodendrogliomas, and ependymomas (Ostrom, Q.T. et al. 2015). Gliomas are graded 
based on histological criteria, nuclear atypia, mitotic activity, endothelial proliferation and 
the presence of necrosis on a scale of I to IV, defined by the World Health Organization 
(WHO) (Alifieris, C. and Trafalis, D.T. 2015; Bush, N.A. et al. 2016).  
Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most common and 
most aggressive malignant primary brain tumour that develops from the lineage of star-
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shaped glial cells, so-called astrocytes (Llaguno-Munive, M. et al. 2013; Thakkar, J.P. et al. 
2014). It constitutes 45.2% of all malignant central nervous system (CNS) tumours and 80% 
of all primary malignant CNS tumours and develops primarily in the cerebral hemispheres 
but can develop in other parts of the brain (Bush, N.A. et al. 2016). The average annual 
age-adjusted incidence rate (IR) of GBM is 3.19/100,000 population (CBTRUS, 2013), and 
a mean age at diagnosis is 64 (Thakkar, J.P. et al. 2014). The IR of GBM is 1.5 times higher 
in males as compared to females, and two times higher in whites than blacks. GBM has a 
worse prognosis with a median overall survival (OS) about 12–18 months after diagnosis 
(Bush, N.A. et al. 2016). Current standard treatment includes maximal-safe surgical 
resection followed by radiotherapy (RT) with concurrent temozolomide (TMZ) 
chemotherapy and adjuvant TMZ for six cycles, depending on the tumour location, the 
cancer cell type and the grade of malignancy (Thakkar, J.P. et al. 2014; Alifieris, C. and 
Trafalis, D.T. 2015). 
The high mitotic activity, microvascular proliferation, and necrosis are characteristic of 
glioblastoma (Hou, L.C. et al. 2006). GBMs are commonly described in two different clinical 
forms: primary (de novo), which correspond to 95% of GBMs, manifest in older patients 
(mean age 62 years) and are typically characterized by amplification of the proto-oncogene 
epidermal growth factor receptor (EGFR) gene, mutations in the telomerase reverse 
transcriptase (TERT) promoter and phosphatase and tensin homolog (PTEN) tumour 
suppressor gene; and secondary, which develop from prior low-grade astrocytomas or 
oligodendrogliomas in younger patients (mean age 45 years) and are characterized by 
mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), tumour protein P53 (TP53), and 
alpha-thalassemia X-linked intellectual disability (ATRX). Mutation in IDH1/2 is one of the 
most important differentiators between primary and secondary GBM (Thakkar, J.P. et al. 
2014; Alifieris, C. and Trafalis, D.T. 2015). 
Methylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter has 
been shown to predict response to alkylating agents such as TMZ, carmustine, and 
cyclophosphamide (Esteller, M. et al. 2002). 
GBM is an aggressive disease that progresses rapidly leading to the appearing of 
various symptoms depending on the size and location of the tumour in the brain. The most 
common symptoms in patients with GBM are headaches, focal neurologic deficits, 
confusion, memory loss and personality changes (Alifieris, C. and Trafalis, D.T. 2015).  
Etiologically, there are known linked risk factors that lead to development of GBM: 
genetic factors (neurofibromatosis, Li-fraumeni syndrome, Von hippel-lindau syndrome and 
Turcot syndrome), environmental factors (prior cranial irradiation and electromagnetic 
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fields), infections (tuberculosis, varicella zoster and simian virus 40) and occupation 
exposures (petroleum industry, exposure to pesticides and chemicals, synthetic rubber 
industry and head trauma) (Schwartzbaum, J.A. et al. 2006; Ostrom, Q.T. et al. 2014; 
Alifieris, C. and Trafalis, D.T. 2015). Other factors associated with GBM risk are high socio-
economic status, taller height, immune factors and immune genes, as well as some single 
nucleotide polymorphisms (SNPs) detected by genome wide association studies. A lower 
risk of gliomas has been associated with allergy or atopic diseases (asthma, eczema, 
psoriasis) (Thakkar, J.P. et al. 2014). 
 
3.1. Immunomodulation in Glioblastoma 
The CNS was once thought to be an immune-privileged site, devoid of normal 
immunologic function. The existence of the blood brain barrier (BBB) that allows for 
selective entry of cells and soluble molecules is one of the main features that support this 
theory. However, contrary to what was thought, the BBB is not limited to CNS immune cell 
entry into cancer and other disease. Nowadays, it is know that the CNS has an active and 
tightly regulated immune system, can elicit vigorous immune-stimulatory as well as 
immunosuppressive responses. Microglia and monocyte-derived macrophages constitute 
the largest fraction of glioma-associated myeloid cells. Microglia, the resident macrophages 
of the CNS, compose 5–20% of the total glial cell population and play an essential role in 
the innate defense system of the brain. Monocyte-derived macrophages are restricted to 
perivascular sites choroid and meningeal CNS, and penetrate the parenchyma after 
disrupted the integrity of BBB due to disease and / or inflammation (Thomas, A.A. et al. 
2012; Reardon, D.A. et al. 2014; Ampie, L. et al. 2015; Perng, P. and Lim, M. 2015).  
Patients with glioblastoma have a relative systemic immune suppression compared to 
the general population (Agrawal, N.S. et al. 2014). The TME is rich with immunosuppressive 
factors secreted by the tumour (figure 10), which induce MHC molecule down regulation, 
production of immunoinhibitory cytokines, polarization of macrophages to the 
immunosuppressive M2 phenotype, infiltration of immunosuppressive Tregs and 
impairment of T cell function due to hostile physical factors such as hypoxia (Reardon, D.A. 
et al. 2014; Nduom, E.K. et al. 2015).  
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Figure 10 - Factors contributing to immunosuppression in glioblastoma. A| Increased expression of 
STAT3 leads to the production of various immunosuppressive factors such as TGFβ-2, PGE, IL-1, IL-10 and 
FGL2 by glioblastoma cells, which suppress the activity of effector cells. M-CSF, TGFβ-1 and IL-10 lead to 
differentiation of macrophages into an M2 phenotype (immunosuppressive). PD-L1 expressed on the surface of 
glioblastoma cells also engages PD-1 to suppress effector activity. B| M2 Macrophages secrete TGFβ-1 and IL-
10, suppressing effector cells further. One of their signatures is production of enzyme Arginase-1 that depletes 
L-arginine thereby suppressing T cell responses and depriving iNOS of its substrate. C| Regulatory T cells 
secrete TGFβ-1 and IL-10 as well, further suppressing immune reactivity, while also expressing PD-L1. D| 
Interaction between the TCR and peptide-MHC provides only a partial signal for cell activation. Full activation 
requires the additional interaction between the costimulatory molecule CD28 on the T cell and CD80/86. 
CD80/86 can also suppress activity by engaging the CTLA4 receptor on the activated T cell. (Adapted from: 
Nduom, E.K. et al. 2015). CD, cluster differentiation; FGL, fibrinogen-like protein; IL, interleukin; M-CSF, 
macrophage colony-stimulating factor; MHC, major histocompatibility complex; PD-1, programmed cell death 
protein 1; PD-L1, programmed death-ligand 1; PGE, prostaglandin E; STAT3, signal transducer and activator 
of transcription 3; TGF, transforming growth factor; Treg, regulatory T cell. 
 
Glioblastoma cells have an increased expression of STAT3, leading to the release 
immunosuppressive factors such as TGF-β2, PGE, IL-1, IL-10 and fibrinogen-like protein 2 
(FGL2)  that suppress the activity of effector cells. FGL2 is a secreted factor that causes 
immunosuppression by increasing the levels of programmed cell death protein 1 (PD-1) 
expression, increased number of M2 macrophages, and enhancing the number of myeloid-
derived suppressor Cells (MDSCs) and Treg. Tumour cells also express on their surface 
programmed death-ligand 1 (PD-L1) which binds to PD-1 to suppress effector activity of T 
cells. M-CSF, TGF-β1 and IL-10 lead to polarization of glioma-infiltrating microglia/tumour 
associated macrophages toward the immunosuppressive M2 phenotype. M2 macrophages 
secrete TGFβ-1 and IL-10, suppressing effector cells further. Treg cells suppress immune 
responses by secreting cytokines, such as TGF-β and IL-10, and by increased expression 
of PD-L1. APCs presented an antigen in context of MHC molecules, requiring a 
costimulatory signal from CD80/86 to CD28 for activation. The CTLA-4, which modulates 
Arginase-1 
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early stages of T-lymphocyte activation, is constitutively expressed on surface of the 
activated T cell and acts as a negative regulator on activation of T cells when bound to 
CD80/86 (Nduom, E.K. et al. 2015; Perng, P. and Lim, M. 2015).  
Locally at the tumour site, GBM cells can inhibit the anti-tumour effector cell responses 
by the expression of soluble and membrane proteins described as immunosuppressive 
molecules (figure 11). Human malignant GBM cells expressing FASL, which binds to FAS 
expressed on immune effector cells triggering apoptosis of these cells. The CD70 is also 
expressed on GBM cells, producing an apoptotic effect on CD27-expressing T and B cells. 
Direct or indirect (via the HLA-E molecule) interaction of HLA-G with inhibitory receptors 
expressed on cytotoxic lymphocytes results in inhibition of cytotoxicity of NK and T cells, in 
decreased T cell proliferation and T-cell priming. IDO is a cytosolic enzyme found in 
gliomas, including GBM, which degrades tryptophan along the kynurenine pathway. 
Kynurenine facilitates expansion of Tregs populations and inhibition of T cell effector 
functions. Other receptors expressed on GBM cells are lectin-like transcript 1 (LLT1) and 
regeneration and tolerance factor (RTF), which inhibit CD161-expressing NK cell 
cytotoxicity and NK and T-cell-mediated cytotoxicity, respectively (Avril, T. et al. 2011; 
Perng, P. and Lim, M. 2015).  
 
Figure 11 - Immunosuppressive molecules expressed on glioblastoma multiforme cells, their molecular 
targets and actions on immune effector cells. Glioblastoma cells also express soluble proteins (IDO and 
TGF-β) and membrane proteins (FASL, CD70, HLA-G, HLA-E, LLT1 and PD-L1) described as 
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immunosuppressive molecules that inhibit the antitumor effector cell responses. (Adapted from: Avril, T. et al. 
2011). CD, cluster differentiation; FASL ,FAS ligand; GBM, glioblastoma multiforme; HLA, human leukocyte 
antigen; IDO, indoleamine 2,3-dioxygenase; KIR, killer-cell immunoglobulin-like receptor; LLT1, lectin-like 
transcript 1; NK, natural killer;  PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; 
RTF, regeneration and tolerance factor; TGF, transforming growth factor; TIL, tumour infiltrating lymphocyte. 
 
3.2. Immunotherapy for the treatment of Glioblastoma 
The immune system can be activated by external stimuli to destroy tumour cells 
effectively, and even to eradicate tumours. In 1891, William Coley observed that some 
patients with sarcoma undergo spontaneous regression of the tumour when they were 
injected with heat kills Streptococcus pyogenes and Serratia Marcescen. This caused an 
increased activity of the immune system against the tumour by systemic immune activation 
(Ampie, L. et al. 2015; Lam, S.S. et al. 2015). This idea boosted for new paths in the 
treatment of cancer with anti-tumour immunotherapy.  
Immunotherapy against cancer is essentially based on the stimulation of the patient’s 
immune system in order to eliminate or neutralize tumour cells and factors that allow tumour 
survival and proliferation. Compared to conventional therapy, immunotherapy using the 
components and the mechanisms of the immune system, inducing no damage to normal 
cells which minimizes side-effects. This therapy has a high therapeutic potential due to 
various immunological characteristics such as, the cognitive character of acquired immunity 
(allowing specificity in anti-tumour responses), the establishment of anti-tumour 
immunologic memory (enabling the prevention of tumour recurrence or keeping it in a state 
of latency) and the effectiveness of the immune response (Arosa, F.A. et al. 2012; Abbas, 
A.K. et al. 2014). 
Applying strategies based on innate and adaptive immunity, they have been developed 
a number of different treatment approaches to stimulate anti-tumour immune responses, 
such as anti-tumour vaccination, adoptive transfer of immune cells, inhibition of immune 
suppression and use of certain cytokines that activate innate immunity cells (Arosa, F.A. et 
al. 2012; Abbas, A.K. et al. 2014). Each of these treatments are designed to increase or 
restore immune function through different mechanisms of action. The mechanisms include 
1), stimulation of anti-tumour response, either by increasing the number of effector cells or 
by producing one or more effector soluble mediators such as cytokines; 2) decreasing 
suppressor mechanisms; 3) modification of tumour cells to increase their immunogenicity 
and make them more susceptible to immunologic defense; and 4) improved tolerance to 
cytotoxic drugs or radiotherapy (Ampie, L. et al. 2015). 
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Immunotherapeutic approaches under clinical development for GBM can broadly be 
classified into cellular therapies, monoclonal antibody therapy, checkpoint blockade and 
vaccine therapy (Table 1) (Reardon, D.A. et al. 2014; Ampie, L. et al. 2015). 
 
Table 1 - Immunotherapy approaches for GBM patients. (Adapted from: Reardon, D.A. et al. 2014) 
Immunotherapeutic Approach Class of Agent Representative Therapeutic 
Cellular Adoptive T-cell transfer  
Chimeric antigen receptor-engineered T cell CTL019 
Vaccination Tumour-associated antigen vaccine  ICT-107; IMA950  
Tumour-specific antigen vaccine  Rindopepimut (EGFRvIII) 
Whole tumour lysate vaccine DCVax 
HSP96 vaccine HSPPC-96 
Tumour-specific mutation vaccine  
Immunomodulation Anti-CTLA-4 Mab Ipilimumab; tremelimumab 
Anti-PD-1 Mab Nivolumab; labrolizumab; pidilizumab 
Anti-PD-L1 MAb BMS-936559;MPDL3280A; MEDI4736 
Treg-depleting reagent Dacluzimab 
 
  
    
 
  
 
 
 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY 
  AIMS OF THE STUDY 
 
27 
 
II. AIMS OF THE STUDY 
The main goal of this project was the evaluation of immunomodulatory capacity of 
extracellular products of glioblastoma cells, in vitro. Thus, our working hypothesis was that 
the products excreted by glioblastoma cells have the ability to modulate host immune 
response. 
Therefore, and in order to confirm our hypothesis we divided our work in specific aims: 
- Evaluate the effect of extracellular products of glioblastoma cell in T-cell activation; 
- Measure the effects of extracellular products of glioblastoma cell in production of 
IL-10 by T cells; 
- Evaluate the effect of extracellular products of glioblastoma cell on function and 
differentiation of macrophages. 
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III. MATERIAL & METHODS 
 
1. Cell culture 
Human glioblastoma astrocytoma cell line U251 was obtained from HPA Culture 
Collections and supplied by Sigma (Sigma product no. 09063001) kindly provided by Dra. 
Paula Soares. U251 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) High 
Glucose (4,5 g/l) medium with Sodium Pyruvate, with Stable Glutamine (Capricorn Scientific 
GmbH), supplemented with 10% fetal bovine serum (FBS, Capricorn Scientific GmbH), 
25mM HEPES (Capricorn Scientific GmbH) and 1% (v/v) penicillin-streptomycin (PenStrep, 
Capricorn Scientific GmbH) at 37ºC in a humidified incubator with 5% CO2. 
Cells were maintained by replacement of fresh medium every three days. Cell lines were 
sub-cultured by trypsinization [Trypsin-EDTA (0.05 %) in DPBS (1x) Capricorn Scientific 
GmbH] when they reached 80% of confluence. Afterwards the cells were frozen in vials with 
freeze medium [complete growth medium supplemented with 10% (v/v) of dimethyl 
sulfoxide (DMSO, Merck Millipore)] in cell freezing containers, containing 1x106 cells/ml.   
 
2. Collection of extracellular products from glioblastoma cells 
culture 
The extracellular products were obtained from cell culture of glioblastoma. A vial of cells 
was thawed and cultured in a 25cm3 flask with DMEM-HG medium supplemented with 20% 
FBS, 25mM HEPES and 1% PenStrep. After two days, the cells were trypsinized and sub-
cultured in three 25cm3 flasks (corresponding to three different time-points). At each time 
point (24, 48 and 72 hours after trypsinization), the extracellular products were collected 
and were separated into high molecular weight  (HMW) and low molecular weight (LMW) 
fractions using Macrosep® Advance Centrifugal Devices 10kDa (Pall Corporation). The 
HMW fraction was filtrated with syringe filters with 0,2 µm of pore size. Afterwards the 
extracellular products were aliquoted and frozen in liquid nitrogen for later use. 
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3. Assay of immunomodulatory capacity of extracellular 
products in PBMCs 
Human mononuclear cells were isolated from peripheral blood of healthy volunteers 
(Centro Hospitalar do Porto, Oporto, Portugal) by Lymphoprep™ (STEMCELL 
Technologies) density centrifugation.  Mononuclear cells were plated in 96-well conical 
bottom plates in RPMI medium supplemented with 10% FBS, 25mM HEPES and 1% 
PenStrep and were treated either with extracellular products of HMW (50% v/v), LMW 
(50%v/v) or with HMW+LMW (50% v/v) or with RPMI. Three hours later, concanavalin A 
from Canavalia ensiformis (Jack bean) (ConcA, 2,5 μg/mL, Sigma-Aldrich®), a mitogen that 
preferentially activates T-cells, was added to the plate and placed at 37ºC in a humidified 
incubator with 5% CO2 overnight (16-24 hours). After incubation, supernatants were 
removed, centrifuged at 500g for 10 min and stored at -80ºC for further quantification of 
cytokines. T-cell activation was assessed by flow cytometry. As a positive control, PBMC 
from healthy donors were treated with culture medium (RPMI) and ConcA. PBMCs from 
healthy donor PBMCs treated only with culture medium (RPMI), was used as a negative 
control.  
4. Flow Cytometry 
PE anti-human CD3 (HIT3a; Biolegend), Biotin anti-human CD69 (FN50; Biolegend) 
and PE/Cy5 Streptavidin (Biolegend) antibodies were used for cell surface staining. Sub-
analysis of the T-cell population activation was based on the gated surface expression of 
CD3 (T cell marker) and CD69 (early activation marker). Flow cytometry acquisition was 
done with BD FACSCantoTM II (BD Biosciences) and data analysis was with FlowJo 
software (TreeStar).  
 
5. Isolation  and differentiation of macrophages 
Human mononuclear cells were isolated from peripheral blood of healthy volunteers 
(Centro Hospitalar do Porto, Oporto, Portugal) by Lymphoprep™ (STEMCELL 
Technologies) density centrifugation.  Mononuclear cells were submitted to a second 
density gradient using Percoll™ (GE Healthcare) to separate monocytes from lymphocytes. 
Subsequently, the monocytes were plated in 96-well flat bottom plates in RPMI medium 
supplemented with 10% FBS, 25mM HEPES and 1% PenStrep. For macrophage 
stimulation 2 g/mL of Recombinant Human Granulocyte Macrophage Colony Stimulating 
Factor (rh GM-CSF, ImmunoTools) was added at the first day of differentiation, and at the 
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third and sixth days was added RPMI medium supplemented with 10% FBS, 25mM HEPES 
and 1% PenStrep and 1 g/mL of rh GM-CSF. At the seventh day the macrophages are 
differentiated. 
 
6. Intracellular killing assay of macrophages modulated by 
extracellular products 
Extracellular products (LMW or HMW fractions) were added with RPMI medium (50% 
v/v) supplemented with 10% FBS and 25mM HEPES (without PenStrep) to the 
differentiated macrophages (7th day). On the 11th day, supernatants were removed for 
further quantification of cytokines and after 3 washes the macrophages were infected with 
1,54x105 CFU/well of bacteria (Staphylococcus aureus). Microplates were incubated for 3h 
at 37ºC in 5% CO2 for bacterial phagocytosis. At different time-points (0h, 3h, 24h and 48h), 
culture supernatants of infected macrophages were removed by aspiration and cells were 
washed three times with RPMI medium supplemented with 20% FBS, 25mM HEPES and 
1% PenStrep to remove extracellular bacteria. To quantify intracellular bacteria, the cells 
were lysed with saponin (0,1% final concentration). After the first time point, the infected 
macrophages, not treated with saponin, were further incubated in extracellular products of 
glioblastoma cell cultures. The colony-forming units (CFUs) of intracellular S. aureus were 
evaluated by plating serial dilutions of the supernatants in Todd-Hewitt agar medium. 
 
7. Enzyme-linked immunosorbent assay (ELISA) 
Detection of IL-10 in the supernatants of PBMCs cultures and detection of IL-10 and 
TNF-α in the supernatants of macrophages cultures was performed with an ELISA kit 
(ImmunoTools, GmbH) according to the manufacturer's instructions. Briefly, MaxiSorp™ 
high protein-binding plates (Nunc) were coated overnight at 4º C with the capture-antibody. 
Afterwards, the blocking-buffer was added to each well and incubate 1h at room 
temperature. After removing the blocking-buffer completely, the sample and the standard 
were added and incubated at room temperature for 2 h. Thereafter, the detector-antibody 
was transferred to each well and incubated 2 h at room temperature. Poly-HRP-
Streptavidin-HS was added and after 30 minutes the TMB substrate was transferred to each 
well. When the enzymatic colour reaction was considered to be sufficient, the reaction was 
stopped by adding the stop solution. It should be noted that between each step the plate 
was washed 5x with washing-buffer.
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IV. RESULTS 
1. Extracellular products from glioblastoma cell culture inhibit T-Cell activation  
T cells recognize pathogen fragments presented by APCs in the context of MHC 
molecules (Xing, Y. and Hogquist, K.A. 2012). Tumour microenvironment is characterized 
by the presence of immunosuppressive factors that can lead to the induction of T-cell 
tolerance or T-cell inactivation (Rabinovich, G.A. et al. 2007).  
To determine if the extracellular products of glioblastoma cell culture could inhibit the 
activation of T-cells, PBMCs from healthy donors were activated with concanavalin A 
(ConcA), a mitogen that preferentially activates T-cells (Krauss, S. et al. 1999), in the 
presence or absence of extracellular products obtained from cell culture of glioblastoma. 
This extracellular products were collected at different time-points and separated into 
different fractions, HMW (high molecular weight) and LMW (low-molecular weight), in order 
to assess if the inhibitory activity is dependent on molecules with high or low molecular 
weight. T-cell activation was assessed by flow cytometry, using the surface marker CD3 to 
identify T cells and the early activation marker CD69 to assess T cell activation. As a positive 
control, PBMC from healthy donors were treated with culture medium (RPMI) and ConcA. 
PBMCs from healthy donor PBMCs treated only with culture medium (RPMI), was used as 
a negative control.  
As depicted in figure 12 we could observe that after ConcA stimulation, the PBMCs from 
healthy donors treated with extracellular products of glioblastoma tumour cells expressed 
lower levels of CD69, when compared with PBMCs treated with ConcA alone. We also 
observe that the lower levels of CD3+CD69+ cells were recorded when both fractions (HMW 
and LMW) were added to PBMC cultures (figura 12B). As shown in figure 12C, the 
percentage of inhibition of T cells is elevated (> 50%) in the presence of both fractions 
(HMW and LMW) and remains practically unchanged for extracellular products collected at 
different time points.  
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Figure 12 - Extracellular products of glioblastoma cell culture reduces CD69 expression on T cells upon 
mitogenic stimulus. PBMCs from healthy donors were treated either with HMW (50% v/v), LMW (50%v/v) or 
with HMW+LMW (50% v/v) or with RPMI (negative control) 3h before incubation with 2.5 μg/mL of ConcA or 
RPMI alone for 20h at 37ºC and 5% CO2. After stimulation, lymphocyte activation was evaluated by flow 
cytometry analysis, using the early activation marker CD69 to assess cell activation. A and B, extracellular 
products of glioblastoma cell culture induce a decrease in the number of CD3+CD69+ compared with positive 
control. A, representative FACS plots are shown. B, the percentage of CD69+ cells is lower in the presence of 
extracellular products of high and low molecular weight (EP HMW+LMW). C, the percentage of inhibition of T 
cells remains practically unchanged in the presence of EP HMW+LMW collected at different time-points. The 
percentage of inhibition of T cells was calculated relative to the measured levels ConcA.  Data are the mean ± 
average deviation from two independent experiments.  
 
2. Effects of extracellular products from glioblastoma cell culture on 
lymphocyte production of IL-10 
IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types 
of cancer (Sato, T. et al. 2011). IL-10 is produced by multiple cell types and has been shown 
to directly affect pro-inflammatory cytokine production, leukocyte activation and 
downregulates the expression of anti-microbial molecules on activated phagocytes (Moore, 
K.W. et al. 2001;Sato, T. et al. 2011). 
To asses if the inhibitory activity of the extracellular products from glioblastoma cell 
cultures observed in Figure 12 was associated with IL-10 production, we quantified IL-10 
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levels in supernatants of PBMC stimulated with ConcA in the presence or absence of the 
extracellular products of glioblastoma cells.  
The results show that higher levels of IL-10 production was observed in PBMCs treated 
with both fractions (HMW and LMW) as compared to lymphocytes treated with ConcA alone 
(figure 13). This was observed for extracellular products collected at different time-points 
and is in accordance to what was observed in Figure 12, where the maximum inhibitory 
activity was observed also when both fractions were added simultaneous to PBMCs. 
Interestingly, we also noted that extracellular products alone were not able to induce IL-10 
production, rather inducing IL-10 production only if an mitogen stimulus was added. 
 
Figure 13 - Quantification of IL-10 in supernatants of lymphocytes treated with extracellular products 
from glioblastoma cell culture. Cytokine production was measured in unstimulated lymphocytes (RPMI), in 
stimulated lymphocytes (ConcA), in lymphocytes treated with the combination of extracellular products of high 
molecular weight and low molecular weight (EP HMW+LMW)  and in lymphocytes treated with the combination 
of extracellular products of high molecular weight and low molecular weight (EP HMW+LMW) plus ConcA. Data 
are the mean ± average deviation from two independent experiments. 
 
3. Effect of extracellular products from glioblastoma cell culture on function 
and differentiation of macrophages  
To investigate the effect of extracellular products from glioblastoma cell culture on the 
ability of macrophages to kill intracellular bacteria, monocytes were isolated from the 
PBMCs of HDs and cultured for 7 d in the presence of GM-CSF. The differentiated 
macrophages were stimulated with the extracellular products of glioblastoma cells, with 
LMW or HMW fractions. After 3 days, Staphylococcus aureus was added to the 
macrophage culture in a multiplicity of infection (MOI) of 1.0. After 3h, the extracellular 
bacteria was removed by washing the wells three times with RPMI plus antibiotic. At the 
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indicated time-points saponin was added to the wells, in order to facilitate the destruction of 
plasma and phagosomal membranes of macrophages by interacting with cholesterols 
(Kaneko, M. et al. 2016), allowing the release of the surviving bacteria into the medium. The 
colony-forming units (CFUs) of intracellular S. aureus were evaluated by plating serial 
dilutions of the supernatants in Todd-Hewitt agar medium.  
Results show an increase of intracellular bacteria in macrophages treated with 
extracellular products from glioblastoma cell culture of high molecular weight (EP HMW) at 
early time-points, namely 3h after the first incubation period (figure 14). When compared to 
the negative control (RPMI), macrophages treated with extracellular products of HMW or 
LMW have a lower ability to kill bacteria after phagocytosis. 
 
 
Figure 14 - Extracellular products from glioblastoma cells reduce macrophage function. Differentiated 
macrophages were treated with RPMI (negative control) or with extracellular products from glioblastoma cell 
culture with high molecular weight (PE HMW) or low molecular weight (EP LMW). 1.54x105 CFU of 
Staphylococcus aureus was added to macrophages cultures and incubated for 3h. After incubation, extracellular 
bacteria was removed. At the indicated time points (0h, 3h, 24h and 48h) saponin was added to the wells and 
intracellular viable bacteria were counted on agar plates. Data are the mean ± average deviation from two 
independent experiments. 
 
Due to the inability of macrophages to kill intracellular bacteria at time-point 'T3', it was 
investigated the effect of extracellular products of glioblastoma culture cells in polarization 
of macrophages into M1 or M2 phenotype. To this end, it was quantified the production of 
the IL-10 and TNF-α by ELISA in the supernatants of macrophage cultures. 
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The IL-10/TNF-α ratio is showed in figure 15. The IL-10 / TNF-α ratio is greater than 1 
in macrophages conditioned with extracellular products of high molecular weight (EP 
HMW), which means that there is increased production of IL-10 compared to production of 
TNF-α by macrophages, indicating a differentiation in a M2 phenotype. This phenotype is 
associated with immunosuppression and contributes in vivo for tumour cell growth 
(Chanmee, T. et al. 2014) . 
 
 
Figure 15 - IL-10/ TNF-α ratio in supernatants of macrophages conditioned with extracellular products. 
Before addition of the bacteria in the previous experiment, supernatants of macrophage cultures were collected.  
IL-10 and TNF-α present in supernatants were quantified by ELISA. Extracellular products with high molecular 
weight (PE HMW) induce an increase in production of IL-10 compared to production of TNF-α. Data are the 
mean ± average deviation from two independent experiments. 
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V. DISCUSSION 
As referred initially, the main purpose of this work was to evaluate the 
immunomodulatory capacity of extracellular products of glioblastoma cells. The 
immunologic properties of extracellular products from glioblastoma cells have not been 
defined previously, and to our knowledge, this is the first study that suggests an 
immunomodulatory effect by extracellular factors produced by tumour cells.  
To investigate the immune properties of extracellular products from glioblastoma cells, 
we used two different experimental approaches. In the first approach, the extracellular 
products from glioblastoma cells were used in immunological assays with PBMCs from 
healthy donors to determine the immunomodulatory effect of these extracellular products in 
the T cells.  In the second approach, differentiated macrophages from monocytes isolated 
from the PBMCs of HDs were conditioned to extracellular products of glioblastoma cell 
cultures, in order to determine the existence of any immunomodulatory effect of extracellular 
products in macrophages, whether through loss of function or through differentiation into 
M2 phenotype.  
T cells are the major players of the adaptive immune system and are able to recognize 
specific antigens presented by APC in the context of MHC molecules. However, in the 
tumour microenvironment T cells can undergo inactivation or tolerization leading to tumour 
escape and progression (Nagaraj, S. et al. 2007;Nurieva, R. et al. 2013;Abbas, A.K. et al. 
2014). Several tumour-derived factors have been implicated in T cell suppression in 
glioblastoma patients. These include TGF-β2, PGE, IL-1, IL-10, IDO and FGL2 (Wrann, M. 
et al. 1987;Nduom, E.K. et al. 2015;Perng, P. and Lim, M. 2015).   
In this work, it was possible to observe that the extracellular products of glioblastoma 
cells, lead to a decrease in T cell activation.  In addition, was observed an increase of IL-10 
production by T cells, which is more indicative of an immunosuppressive environment. IL-
10 is an anti-inflammatory cytokine secreted by numerous cell types of the innate and 
adaptive immune system, which limits the excess of inflammation and prevents tissue 
damage (Dennis, K.L. et al. 2013). T cells, monocytes, macrophages, and DCs are 
particularly important both as targets and actors of IL-10-mediated immunosuppression 
(Moore, K.W. et al. 2001). Furthermore, IL-10 can also hinder cytotoxic T-lymphocyte 
effector functions by inducing and sustaining FOXP3 transcription factor expression in 
immunosuppressive Treg cells (Murai, M. et al. 2009). Cumulatively, the data presented 
herein could indicate that there is something secreted by the tumour, which contributes to 
immunosuppression, not only by inhibiting T cell activation, but also by the induction of 
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regulatory T cells in the tumour environment as a result of the increase in IL-10 production. 
Tregs, known as suppressor T cells, are able to suppress the proliferation of antigen-
stimulated naïve T cells and other immune cells (B cells, NK cells, NKT cells, monocytes 
and DCs) (Schmidt, A. et al. 2012).  
Macrophages, which are innate immune cells that play a broad role in host defense and 
the maintenance of tissue homeostasis, can be polarized into M1 or M2 phenotype 
depending on the microenvironment. Upon activation, M1 macrophages produce 
proinflammatory cytokines like TNF-α, IL-6, IL-12 and IL-23 (Chanmee, T. et al. 2014; 
Wang, N. et al. 2014). In contrast, M2 macrophages produce high levels of IL-10, have been 
considered to exert a tumour-promoting influence (Sica, A. et al. 2006; Hao, N.B. et al. 
2012). Tumour-associated macrophages (TAMs) exhibit functions similar to those of M2 
macrophages, can be activated in malignant tumours, and this may contribute to tumour 
metastasis, angiogenesis and immunosuppression (Mantovani, A. and Sica, A. 2010; Qian, 
B.Z. and Pollard, J.W. 2010). 
In this report, we also showed that the extracellular products of high molecular weight 
of glioblastoma cells serves as a key regulator of macrophages differentiation. Our results 
indicate that there is something that actually is being secreted by glioblastoma cells, which 
leads to polarization to macrophages into M2 phenotype. This is supported by the increased 
of IL-10 production accompanied by a decrease of TNF-α production.  
One of the main functions of macrophages is engulf the infectious agents, internalizing, 
and destroying them (Underhill, D.M. and Goodridge, H.S. 2012). Interestingly, we also 
observed that polarization of macrophage into M2 phenotype is associated with inhibition 
of specific function of macrophages, i.e., macrophages exhibit a decreased ability to kill 
intracellular bacteria after phagocytosis. 
Different experimental approaches consistently showed that there is something 
excreted by tumour cells that exerts a direct immunomodulation on host immune cells, 
inducing IL-10 production by T cells and macrophages, decrease the T cell activation, and 
inducing the differentiation of monocytes into macrophages M2.  
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VI. CONCLUSION 
The present study comprised the evaluation of the immunomodulatory capacity of 
extracellular products of glioblastoma cells. To this end, it evaluated the ability of 
extracellular products either to induce IL-10 production by T-cells or to inhibit T cell 
activation. It was also evaluated the effect of extracellular products in function and 
differentiation of macrophages. 
Regardless of the experimental approaches, the data consistently demonstrated that 
there is something effectively secreted by tumour cells that exerts a direct 
immunomodulation on host immune cells, inducing IL-10 production by T cells and 
macrophages, decrease the T cell activation, and inducing the differentiation of monocytes 
into macrophages M2. 
In summary, this study allows to infer an impact of extracellular products of glioblastoma 
cells in suppression of the immune response. Moreover, as it is something excreted can act 
from a distance, i.e., it is not something structural, blocking the immune response against 
tumour antigens, even being very specific. This fact could explain why immunotherapies 
directed against surface or structural antigens of tumours have failed.  
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